Table 1.

Clinical Characteristics of Study Infants*

Controls
n = 12
Furosemide
n = 7
Thiazide
n = 5
Furosemide and Thiazide
n = 8
Birth weight (g)1139.8  ± 56.8843.4  ± 47.3944.2  ± 75818.9  ± 62.3
Gestational age at birth (wk)28.4  ± 0.426.0  ± 0.326.8  ± 0.225.1  ± 0.4
Gestational age at study (wk)34.9  ± 0.334.0  ± 0.634.2  ± 0.733.9  ± 0.7
Postnatal age at study (days)45.6  ± 3.354.6  ± 3.352.4  ± 4.562.4  ± 4.5
Intake (mL/kg/d)152.7  ± 5.5137.7  ± 7.5167.1  ± 8.8156.6  ± 3.5
Urinary creatinine (mg%)13.2  ± 1.511.9  ± 1.710.1  ± 0.813.6  ± 1.5
Calcium intake (mg/kg/d)203.1  ± 12.7191.6  ± 12.2233.0  ± 14.1222.9  ± 6.3
Phosphorus intake (mg/kg/d)104.8  ± 3.795.7  ± 6.1116.7  ± 7.1113.9  ± 2.6
Sodium intake (mEq/kg/d)2.3  ± 0.13.5  ± 0.64.7  ± 0.79.2  ± 0.4
Potassium intake (mEq/kg/d)4.1  ± 0.24.2  ± 0.46.3  ± 1.18.1  ± 0.9
Chloride intake (mEq/kg/d)2.8  ± 0.14.2  ± 0.65.7  ± 0.812.4  ± 0.8
Ascorbate intake (mg/kg/d)51.3  ± 3.943.4  ± 5.060.9  ± 8.247.1  ± 3.7
Furosemide (mg/kg/d)0.8  ± 0.060.9  ± 0.02
Thiazide (mg/kg/d)22.8  ± 5.518.7  ± 2.7
  • * Expressed as mean ± SEM.

  • P < .05 compared to control infants.

  • P < .01 compared to control infants.